Servier Expands Cellectis UCART19 Collaboration
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 2 (Table of Contents)
Published: 21 Feb-2020
DOI: 10.3833/pdr.v2020.i2.2513 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Servier has expanded its collaboration agreement with Cellectis to develop and commercialise allogenic CAR-T products targeting CD19, including rights to ALLO-501A...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS